Skip to main content
. 2015 May 22;10(5):e0128159. doi: 10.1371/journal.pone.0128159

Fig 4. Suppression of c-Met in c-Met+ HCC upregulates ErbB3 predominantly through the PI3K/Akt signaling arm.

Fig 4

(A) EGFR, ErbB2, and ErbB3 mRNA by qRT-PCR and (B) ErbB3 protein expression by immunoblot in MHCC97-H cells treated with c-Met inhibitor PHA665752 (1 μM) 48 hours after treatment. (C) ErbB3 mRNA by qRT-PCR and (D) protein by immunoblot in MHCC97-H cells treated with c-Met inhibitor PHA665752 (1 μM), PI3K inhibitor LY290042 (25 μM), or Mek inhibitor PD98059 (50 μM) 48 hours after treatment.